Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).
Robert B. Montgomery
Consultant or Advisory Role - Ipsen
Research Funding - Cougar Biotechnology; Tokai
Mario A. Eisenberger
Consultant or Advisory Role - Astellas Pharma; Millennium; Sanofi
Honoraria - Bristol-Myers Squibb; Millennium
Research Funding - Astellas Pharma; Sanofi ; Tokai
Matthew Rettig
No relevant relationships to disclose
Franklin Chu
No relevant relationships to disclose
Roberto Pili
Research Funding - Tokai
Joe Stephenson
Research Funding - Tokai
Nicholas J. Vogelzang
Consultant or Advisory Role - Amgen; Celgene; Cougar Biotechnology; GlaxoSmithKline; Takeda
Honoraria - Bayer; Cougar Biotechnology; Genentech; Johnson & Johnson; Veridex
Research Funding - Algeta; Cougar Biotechnology; Johnson & Johnson; Novartis; Pfizer; Takeda; Tokai
Jodie Morrison
Employment or Leadership Position - Tokai
Stock Ownership - Tokai
Mary-Ellen Taplin
Research Funding - GlaxoSmithKline; Johnson & Johnson; Tokai